Stoke Therapeutics, INC Form 4 insider transactions

Stoke Therapeutics CEO, Edward M. Kaye, sold 6,786 shares of common stock to cover tax liabilities related to the vesting of restricted stock units.

A Stoke Therapeutics executive sold shares to cover tax liabilities related to vested stock units.

A Stoke Therapeutics executive sold shares to cover tax liabilities related to the vesting of restricted stock units.

Stoke Therapeutics CEO, Edward M. Kaye, sold 6,170 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Stoke Therapeutics CEO Edward M. Kaye received performance-based restricted stock units, with an amended filing correcting the number of units awarded and vested.

Jonathan Allan, General Counsel & Corporate Secretary at Stoke Therapeutics, reported the acquisition of 6,000 common stock shares and 12,000 performance stock units, and the vesting of 6,000 performance stock units.

Stoke Therapeutics CEO Edward M. Kaye acquired 26,500 shares and 53,000 performance stock units on December 3, 2024.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, acquired 10,000 shares of common stock and 20,000 performance stock units, while also converting 10,000 performance stock units into common stock.

Jonathan Allan, General Counsel & Corporate Secretary at Stoke Therapeutics, reports the acquisition of 33,927 shares of common stock and 33,927 restricted stock units on December 1, 2024.

Stoke Therapeutics CEO, Edward M. Kaye, exercised stock options and received restricted stock units, resulting in a change in his beneficial ownership of the company's stock.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, engaged in multiple stock transactions, including the vesting of restricted stock units and the sale of common stock.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold 10,000 shares of common stock on November 1, 2024, according to a Form 4 filing with the SEC.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold 10,000 shares of common stock on October 1, 2024, according to a Form 4 filing with the SEC.

Skorpios Trust, along with related entities, disposed of 1,937,500 shares of Stoke Therapeutics at $14.05 per share, reducing their holdings but maintaining significant ownership.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Chief Medical Officer of Stoke Therapeutics, Barry Ticho, exercised stock options and sold 10,000 shares of common stock on August 1, 2024, according to a Form 4 filing.

Huw M. Nash, Chief Business Officer of Stoke Therapeutics, sold shares of common stock on July 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold 10,000 shares of common stock on July 1, 2024, under a pre-arranged 10b5-1 trading plan.

CEO Edward M. Kaye of Stoke Therapeutics, Inc. reports acquisition of stock options and restricted stock units.

Huw M. Nash, COO & CBO of Stoke Therapeutics, reports the acquisition of stock options and restricted stock units.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, reports the acquisition of stock options and restricted stock units.

Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, reports the acquisition of stock options and restricted stock units.

Former CFO of Stoke Therapeutics, Stephen J Tulipano, reports the acquisition of stock options and restricted stock units.

Director Seth Loring Harrison acquired stock options in Stoke Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing with the SEC.

Director Jennifer Burstein acquired stock options in Stoke Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing with the SEC.

Director Julie Smith of Stoke Therapeutics, Inc. was granted stock options on June 5, 2024, according to a Form 4 filing with the SEC.

Director Ian F. Smith acquired stock options in Stoke Therapeutics, Inc. on June 5, 2024.

Director Garry Menzel acquired 7,639 stock options in Stoke Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing with the SEC.

Arthur Tzianabos, a director at Stoke Therapeutics, acquired stock options exercisable for 7,639 shares of common stock.

Director Arthur Levin acquired stock options in Stoke Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing with the SEC.